Cambridge Healthtech Institute's Fourth Annual

Engineering Next-Generation Cancer Immunotherapies

( 次世代癌症免疫疗法的开发 )

New Protein Engineering Science and Technology to Support the Development of Novel Immunotherapeutics and Treatment Combinations

2018年1月8日 - 9日


A succession of strong clinical successes with antibodies against checkpoint targets has spawned a surge of interest from across the industry in the development of antibody immunotherapeutics and treatment combinations. The major challenges facing those now entering the field include establishing clinical proof-of-concept, product and target differentiation, selection of patient responders and the rational design of effective immunotherapy combinations. Cambridge Healthtech Insitute's Fourth Annual Engineering Next-Generation Cancer Immunotherapies meeting offers presentations of protein engineering strategies to improve the efficacy of immunotherapeutics and drive the progress of more personalized treatments in this space.

We invite presentation proposals on the following preliminary topics:

  • Antibody mixtures as an alternative to bispecifics
  • Balancing efficacy and safety in developing second-generation IO products
  • Emerging immunotherapy targets and pathways
  • Engineering challenges in targeting the tumor microenvironment
  • Enhancing immunotherapy efficacy in solid tumors
  • Immune repertoire profiling for personalized immunotherapy
  • Immune system priming and activation
  • Internal development of immunotherapy backbones (anti-PD-1, anti-PD-L1, anti-CTLA-4)
  • Neoantigen-based cancer vaccines
  • High throughput screening of patient derived xenografts
  • Rational design of immunotherapy bispecifics and combinations
  • Resolving immunogenicity in engineered immunotherapies

* 活动内容有可能不事先告知作更动及调整。